674
Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study.
 ( potential therapeutic event: in ,  Weekly AUC2 carboplatin: Treatment, with or without oral phenoxodiol: Treatment, Weekly: Treatment.Freq, AUC2 carboplatin: Treatment.Drug, phenoxodiol: Treatment.Drug, platinum-resistant ovarian cancer: Treatment.Disorder, oral: Treatment.Route, phenoxodiol: Combination.Drug, AUC2 carboplatin: Combination.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( potential therapeutic event: in ,  Weekly AUC2 carboplatin: Treatment, with or without oral phenoxodiol: Treatment, Weekly: Treatment.Freq, AUC2 carboplatin: Treatment.Drug, phenoxodiol: Treatment.Drug, platinum-resistant ovarian cancer: Treatment.Disorder, oral: Treatment.Route, phenoxodiol: Combination.Drug, AUC2 carboplatin: Combination.Drug) 